Link Pharma Chem
BSE: LINKPH · Commodity Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Link Pharma Chem's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Link Pharma Chem Limited is an Indian manufacturer specialising in organic intermediate chemicals, aromatic compounds, and fine chemicals. The company serves the pharmaceutical and agrochemical industries through its production facility in the Nandesari industrial estate.
Business Model
The company generates revenue by producing and supplying chemical intermediates, including tosylates and derivatives, for active pharmaceutical ingredient synthesis. It operates as a niche player focusing on custom synthesis and bulk chemical intermediate manufacturing.
Growth Outlook
Growth is driven by the company's technical expertise in complex chemical reactions and its established presence in the specialty chemicals sector. It aims to leverage its position in both domestic and international markets to expand its custom synthesis footprint.
Key Risks
- Regulatory Compliance. The company faces stringent environmental and safety regulations inherent to the chemical manufacturing sector in India.
- Raw Material Price Volatility. Fluctuations in the cost of petrochemical feedstocks can significantly impact profit margins due to the commodity nature of certain intermediates.
- Market Concentration. As a small-cap entity, the company may be vulnerable to shifts in demand from the pharmaceutical and agrochemical sectors.
- Operational Risks. Concentration of manufacturing activities in a single facility at the Nandesari industrial estate creates exposure to site-specific operational disruptions.
Start your research today
Unlock AI insights, financials, peers and live data on Link Pharma Chem and 5,000+ companies — free.
Key Metrics
REVENUE
₹27 Cr
TTM · standalone
NET PROFIT
₹-0.42 Cr
TTM · standalone
EPS
₹-0.93
TTM · standalone
RETURN ON EQUITY
-3.2%
TTM · standalone
P/E
-29.0x
Q3 FY25 · standalone
EV/EBITDA
13.4x
Q3 FY25 · standalone
EBITDA MARGIN
5.0%
TTM · standalone
NET PROFIT MARGIN
1.0%
Q3 FY26 · standalone
DEBT TO EQUITY
0.6x
Q4 FY25 · standalone
Peers · Commodity Chemicals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Link Pharma ChemLINKPH | ₹12 Cr | -30.05 | 14.46 | -13.3% | 5.0% | -3.2% | 2.6% | -15.7% |
Blue Pearl Agriventures LimitedBPAGRI | ₹525 Cr | — | — | — | 2.7% | — | — | -92.2% |
Primo ChemicalsPRIMO | ₹517 Cr | 32.82 | 7.31 | -2.7% | 15.8% | 4.0% | 7.1% | -16.6% |
POCL EnterprisesPOEL | ₹460 Cr | 10.53 | 7.57 | — | 5.3% | 21.3% | 33.7% | -37.2% |
Mangalam OrganicMANORG | ₹437 Cr | 21.41 | 8.88 | 17.3% | 13.6% | 6.8% | 15.9% | -7.2% |
Lords Chloro Alkali LimitedLORDSCHLO | ₹402 Cr | 11.52 | 7.91 | 29.8% | 17.3% | 15.6% | 14.1% | -18.7% |
As of Q3 FY25
Financials
Link Pharma Chem
BSE: LINKPH · Commodity Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Link Pharma Chem's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Link Pharma Chem Limited is an Indian manufacturer specialising in organic intermediate chemicals, aromatic compounds, and fine chemicals. The company serves the pharmaceutical and agrochemical industries through its production facility in the Nandesari industrial estate.
Business Model
The company generates revenue by producing and supplying chemical intermediates, including tosylates and derivatives, for active pharmaceutical ingredient synthesis. It operates as a niche player focusing on custom synthesis and bulk chemical intermediate manufacturing.
Growth Outlook
Growth is driven by the company's technical expertise in complex chemical reactions and its established presence in the specialty chemicals sector. It aims to leverage its position in both domestic and international markets to expand its custom synthesis footprint.
Key Risks
- Regulatory Compliance. The company faces stringent environmental and safety regulations inherent to the chemical manufacturing sector in India.
- Raw Material Price Volatility. Fluctuations in the cost of petrochemical feedstocks can significantly impact profit margins due to the commodity nature of certain intermediates.
- Market Concentration. As a small-cap entity, the company may be vulnerable to shifts in demand from the pharmaceutical and agrochemical sectors.
- Operational Risks. Concentration of manufacturing activities in a single facility at the Nandesari industrial estate creates exposure to site-specific operational disruptions.
Start your research today
Unlock AI insights, financials, peers and live data on Link Pharma Chem and 5,000+ companies — free.
Key Metrics
REVENUE
₹27 Cr
TTM · standalone
NET PROFIT
₹-0.42 Cr
TTM · standalone
EPS
₹-0.93
TTM · standalone
RETURN ON EQUITY
-3.2%
TTM · standalone
P/E
-29.0x
Q3 FY25 · standalone
EV/EBITDA
13.4x
Q3 FY25 · standalone
EBITDA MARGIN
5.0%
TTM · standalone
NET PROFIT MARGIN
1.0%
Q3 FY26 · standalone
DEBT TO EQUITY
0.6x
Q4 FY25 · standalone
Peers · Commodity Chemicals
As of Q3 FY25